Literature DB >> 18292563

Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection.

Weidang Li1, Ashlesh K Murthy, M Neal Guentzel, J Seshu, Thomas G Forsthuber, Guangming Zhong, Bernard P Arulanandam.   

Abstract

Chlamydia has been shown to evade host-specific IFN-gamma-mediated bacterial killing; however, IFN-gamma-deficient mice exhibit suboptimal late phase vaginal Chlamydia muridarum clearance, greater dissemination, and oviduct pathology. These findings introduce constraints in understanding results from murine chlamydial vaccination studies in context of potential implications to humans. In this study, we used mice deficient in either IFN-gamma or the IFN-gamma receptor for intranasal vaccination with a defined secreted chlamydial Ag, chlamydial protease-like activity factor (CPAF), plus CpG and examined the role of IFN-gamma derived from adoptively transferred Ag-specific CD4+ T cells in protective immunity against genital C. muridarum infection. We found that early Ag-specific IFN-gamma induction and CD4+ T cell infiltration correlates with the onset of genital chlamydial clearance. Adoptively transferred IFN-gamma competent CPAF-specific CD4+ T cells failed to enhance the resolution of genital chlamydial infection within recipient IFN-gamma receptor-deficient mice. Conversely, IFN-gamma production from adoptively transferred CPAF-specific CD4+ T cells was sufficient in IFN-gamma-deficient mice to induce early resolution of infection and reduction of subsequent pathology. These results provide the first direct evidence that enhanced anti-C. muridarum protective immunity induced by Ag-specific CD4+ T cells is dependent upon IFN-gamma signaling and that such cells produce sufficient IFN-gamma to mediate the protective effects. Additionally, MHC class II pathway was sufficient for induction of robust protective anti-C. muridarum immunity. Thus, targeting soluble candidate Ags via MHC class II to CD4+ T cells may be a viable vaccine strategy to induce optimal IFN-gamma production for effective protective immunity against human genital chlamydial infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292563     DOI: 10.4049/jimmunol.180.5.3375

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.

Authors:  Weidang Li; Ashlesh K Murthy; M Neal Guentzel; James P Chambers; Thomas G Forsthuber; J Seshu; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

2.  Antigen-Specific CD4+ T Cell-Derived Gamma Interferon Is Both Necessary and Sufficient for Clearing Chlamydia from the Small Intestine but Not the Large Intestine.

Authors:  Hui Lin; Conghui He; John J Koprivsek; Jianlin Chen; Zhiguang Zhou; Bernard Arulanandam; Zhenming Xu; Lingli Tang; Guangming Zhong
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

3.  T cell responses in the absence of IFN-gamma exacerbate uterine infection with Chlamydia trachomatis.

Authors:  David C Gondek; Nadia R Roan; Michael N Starnbach
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

4.  IgA modulates respiratory dysfunction as a sequela to pulmonary chlamydial infection as neonates.

Authors:  Gopala Krishna Koundinya Lanka; Jieh-Juen Yu; Siqi Gong; Rishein Gupta; Shamimunisa B Mustafa; Ashlesh K Murthy; Guangming Zhong; James P Chambers; M Neal Guentzel; Bernard P Arulanandam
Journal:  Pathog Dis       Date:  2016-01-10       Impact factor: 3.166

5.  A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.

Authors:  Weidang Li; Ashlesh K Murthy; Gopala Krishna Lanka; Senthilnath L Chetty; Jieh-Juen Yu; James P Chambers; Guangming Zhong; Thomas G Forsthuber; M Neal Guentzel; Bernard P Arulanandam
Journal:  Vaccine       Date:  2013-10-01       Impact factor: 3.641

6.  Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice.

Authors:  Jieh-Juen Yu; Tatareddy Goluguri; M Neal Guentzel; James P Chambers; Ashlesh K Murthy; Karl E Klose; Thomas G Forsthuber; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-12-16

7.  Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.

Authors:  Bharat K R Chaganty; Ashlesh K Murthy; Shankar J Evani; Weidang Li; M Neal Guentzel; James P Chambers; Guangming Zhong; Bernard P Arulanandam
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

8.  A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge.

Authors:  Ashlesh K Murthy; Bharat K R Chaganty; Weidang Li; M Neal Guentzel; James P Chambers; J Seshu; Guangming Zhong; Bernard P Arulanandam
Journal:  FEMS Immunol Med Microbiol       Date:  2009-03

9.  A Chlamydia-Specific TCR-Transgenic Mouse Demonstrates Th1 Polyfunctionality with Enhanced Effector Function.

Authors:  Taylor B Poston; Yanyan Qu; Jenna Girardi; Catherine M O'Connell; Lauren C Frazer; Ali N Russell; McKensie Wall; Uma M Nagarajan; Toni Darville
Journal:  J Immunol       Date:  2017-08-30       Impact factor: 5.422

10.  Identifying catalytic residues in CPAF, a Chlamydia-secreted protease.

Authors:  Ding Chen; Jijie Chai; P John Hart; Guangming Zhong
Journal:  Arch Biochem Biophys       Date:  2009-05-01       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.